Indiana is currently home to 1214 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Leg Heat Therapy in Peripheral Artery Disease
NCT05465070
Recruiting
The goal of this randomized, double-blind, sham-controlled clinical trial is to evaluate the benefits of home-based, leg heat therapy (HT) on lower-extremity functioning and quality of life in patients who suffer from lower-extremity peripheral artery disease (PAD). We will randomize 106 patients to one of two groups that either receive leg HT or a sham intervention. The primary study outcome is the change in 6-minute walk distance between baseline and the 12-week follow up. Secondary outcomes i... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/23/2025
Locations: Indiana University Health Methodist Hospital, Indianapolis, Indiana
Conditions: Peripheral Artery Disease
Register for Updates
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana
Conditions: Hypertriglyceridemia
Register for Updates
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
NCT06614192
Recruiting
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Community Cancer Center North /ID# 267965, Indianapolis, Indiana
Conditions: Metastatic Colorectal Cancer
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Parkview Research Center, Fort Wayne, Indiana
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study of YL201 in Patients with Advanced Solid Tumors
NCT05434234
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Community Health Network, Indianapolis, Indiana
Conditions: Advanced Solid Tumor
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: Gastroenterology Health Partners, PLLC - Southern Indiana, New Albany, Indiana
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Enhancing Prospective Thinking in Early Recovery (HOME)
NCT06302413
Recruiting
The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering alcohol use disorder (AUD) persons. The main question\[s\] this trial aims to answer are: Will the Virtual Reality (VR) intervention decrease the number of stimulant use days? Will the VR intervention produce longer abstinen... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/19/2025
Locations: Indiana University School of Medicine - Goodman Hal, Indianapolis, Indiana
Conditions: Alcohol Use Disorder
Register for Updates
Enhancing Prospective Thinking in Early Recovery (NERF)
NCT06283446
Recruiting
The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are: Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? Will high-intensity EFT cues effect greater treatment-seeking interest? Will high-intensity EFT cues elicit greater response in regions for pr... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/19/2025
Locations: Indiana University School of Medicine - Goodman Hall, Indianapolis, Indiana
Conditions: Alcohol Use Disorder
Register for Updates
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
NCT04889911
Recruiting
The overall purpose of the proposed exploratory intervention development application, is to conduct research that will inform the adaptation and preliminary testing of NECT modified for youth (aged 15-24) with first episode psychosis (FEP), targeting self-concept and illness conceptions to increase treatment engagement. The specific aims of the project are to: 1) adapt NECT to be responsive to the needs and preferences of youth with FEP, and 2) Assess the feasibility, acceptability and prelimina... Read More
Gender:
ALL
Ages:
Between 15 years and 24 years
Trial Updated:
03/19/2025
Locations: Eskenazi Health, PARC Program, Indianapolis, Indiana
Conditions: First Episode Psychosis, Youth
Register for Updates
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Intravenous Iron in Combination with Standard of Care Immunotherapy in Melanoma
NCT06508827
Recruiting
Anemia is a common complication among cancer patients and is negatively associated with overall prognosis and therapeutic outcomes. The purpose of this study is to see if giving a dose of iron prior to any standard of care chemotherapy treatment will affect the cells that are believed to make treating melanoma harder, making melanoma more responsive to the standard of care immunotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Anemia, Iron Deficiency, Melanoma
Register for Updates
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
NCT05904691
Recruiting
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/18/2025
Locations: Raj K. Maturi, M.D., P.C., Carmel, Indiana
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates